Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 3Tumor-Agnostic 1Plasma cell 1Other hematologic neoplasm 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Esophageal Neoplasms 1

Interventions

Oxaliplatin 1409Fluorouracil 1298Capecitabine 1085Gemcitabine 1042Leucovorin 928Irinotecan 815Bevacizumab 803Cisplatin 666Radiotherapy 535Cetuximab 469pembrolizumab 428Paclitaxel 389Nivolumab 336130-nm albumin-bound paclitaxel 322Drug Therapy 314Docetaxel 286S 1 (combination) 273Sorafenib 266Folfox protocol 261Albumin-Bound Paclitaxel 259sintilimab 211durvalumab 209Surgical Procedures, Operative 203tislelizumab 202Radiosurgery 202lenvatinib 201apatinib 198Carboplatin 186Magnetic Resonance Spectroscopy 181regorafenib 180

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Vaccination × Gastrointestinal × Clear all
NCT01267578 2010-12-28

Peptide Vaccination in Treating Patients With Esophageal Cancer (STF-II)

University of Yamanashi

Phase 2 Unknown
60 enrolled
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡